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Abstract
We conducted a meta analysis of Parkinson’s disease genome-wide association studies using a 
common set of 7,893,274 variants across 13,708 cases and 95,282 controls. Twenty-six loci were 
identified as genome-wide significant; these and six additional previously reported loci were then 
tested in an independent set of 5,353 cases and 5,551 controls. Of the 32 tested SNPs, 24 
replicated, including 6 novel loci. Conditional analyses within loci show four loci including GBA, 
GAK/DGKQ, SNCA, and HLA contain a secondary independent risk variant. In total we identified 
and replicated 28 independent risk variants for Parkinson disease across 24 loci. While the effect 
of each individual locus is small, a risk profile analysis revealed a substantial cummulative risk in 
a comparison highest versus lowest quintiles of genetic risk (OR=3.31, 95% CI: 2.55, 4.30; p-
value = 2×10−16). We also show 6 risk loci associated with proximal gene expression or DNA 
methylation.
Increasing evidence supports the extensive and complex genetic contribution to Parkinson’s 
disease (PD). Genome-wide association (GWA) studies have shed light on the genetic basis 
of this disease, with the identification and replication of risk loci that fit the common disease 
common variant hypothesis.1–17 The loci identified have both affirmed the central role of 
genes previously linked to PD and implicated new proteins in the pathogenic cascade.18 
These data have also shown that thus far only a small portion of the heritable component of 
PD has been identified.19 Experience in other complex diseases and traits demonstrates that 
ever greater resolution of genetic risk can be achieved through larger sample sizes and that 
common genetic variability may play a more substantial role in complex traits than 
previously anticipated.20–22 With each of these factors in mind, we performed a meta-
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analysis of all existing European ancestry PD GWA study data and a replication study in an 
independent data set.
We performed a meta-analysis of genome-wide SNP data from 13,708 PD patients and 
95,282 controls. This approach required imputation using the August 2010 release of the 
1000 Genomes Project European ancestry haplotype reference set to standardize data to over 
11 million variants.23 Only markers that were successfully imputed in at least three datasets 
and that had a meta-analysis wide sample size weighted minor allele frequency of 0.1% or 
more were included (n=7,893,274). The genomic inflation factor for each of the datasets 
ranged from 0.889 to 1.056 (based on lambda values standardized to a scale of 1000 cases 
and 1000 controls, see Supplementary Table 1 for study specific details). Fixed-effect meta-
analysis of the summary statistics from each set revealed 26 loci associated with risk for 
disease in the discovery phase, based on a widely-accepted genome-wide p-value threshold 
of 5×10−8 (Table 1 and Figure 1 with additional details in Supplementary Table 2 and 
Supplementary Figure 1).24
To identify which of the putatively associated loci were truly disease-related, we attempted 
to replicate each locus in an independent sample series using a semi-custom genotyping 
array called NeuroX. This array typed >240,000 exonic variants available on Illumina’s 
Infinium HumanExome BeadChip and an additional ~24,000 variants proven or 
hypothesized to be relevant in neurodegenerative disease [Nalls et al., in review]. Within the 
custom content we included the 26 genome-wide significant candidate loci implicated in PD 
from the primary meta-analysis. For each independent locus the most significantly 
associated SNP and a series of proxy variants were included in the array design. Following 
stringent quality control, high quality genotype data were available for a sample set of 5,353 
cases and 5,551 controls (see Online Methods for complete details). Association analysis 
revealed replication of 22 of 26 loci tested based on a nominal 1-sided p-value of <0.05 and 
consistent direction of association which incorporates the premise of prior knowledge for 
most loci based on previous meta-GWAS (Table 1); of these loci, six were novel (SIPA1L2, 
INPP5F, MIR4697, GCH1, VPS13C, DDRGK1). In addition we examined association at six 
loci previously reported to be associated with risk for PD but that did not show association 
at p<5×10−8 in the discovery phase.1,2,4,25 While these loci have been reported in samples 
derived from some of the cohorts included in the discovery phase of this meta-analysis, 
individuals in the replication samples were distinct from those used to nominate these loci. 
We found evidence for association based on a nominal 1-sided p-value of <0.05 in the 
replication data at two of these loci in our replication phase analyses (FGF20 and SREBF/
RAI1; Table 1). We do note that some loci did not replicate, these loci included regions of 
high effect heterogeneity and low effect sizes (~1.1 odds ratio), for which our replication 
series may have been slightly underpowered. For example, at an odds ratio of 1.1 and an 
allele frequency of 5%, our replication series were only at a power of ~35% to reach our 
designated alpha; while under the assumption of no effect heterogeneity across the 
replication samples and no winner’s curse phenomenon, we were at ~80% power to reach 
our target alpha for replication if the allele frequency is increased to 40% and the odds ratio 
remains 1.1. We recognize that study heterogeneity contributed to some of this non-
replication (as evidenced by the I2 metric in Supplementary Table 2), particularly in the 
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discovery phase of analyses. In the discovery phase, the associations at rs115185635 and 
rs1555399 were driven almost completely by the IPDGC-UK cohort and highly 
heterogenous across cohorts (I2 estimates at 91.0 and 97.2 respectively). In addition, 
rs115185635 was a very difficult variant to impute likely due to its frequency, as it passed 
quality control in only 8 of our participating studies. We do not believe there is any major 
issue with the UK data based on both previously published studies, as well as consistent 
effects at more established loci evidenced by I2 metrics in Supplementary Tables 2 and 3, as 
well as in Supplementary Table 1 and Supplementary Figures 2 – 4 describing study specific 
effect estimates in addition to genomic inflation factors. Our strategy of a distinct replication 
phase was instituted primarily to confirm suspect novel loci and to exclude any types of 
systematic issues that may lead to false positives at individual loci.
We tested whether multiple independent risk alleles existed at any of the 26 genome-wide 
significant loci identified in the discovery phase. For each locus we tested all variants within 
1 million base pairs of the index SNP with the most extreme p-value. To identify risk alleles 
independent of the primary effect, the index SNP was included as a covariate in the model 
(0, 1 or 2 copies of the minor allele). Additional independent risk variants were identified at 
8 of the loci (9.31×10−6 to 7.09×10−19) and were also included on the replication array. Four 
of these variants revealed significant association upon conditional analysis of the replication 
phase data (Table 2 and Supplementary Table 3 for additional details).
Risk profiles were generated for each subset of replication samples separately using all 
SNPs with replication phase p-values less than the marginal one-sided p-value of 0.05 
(discovery, candidate and conditional phases, Tables 1 and 2). These 28 SNPs were used to 
compute genetic risk profile scores (for additional risk profiling methods, please see Online 
Methods). Similar to previous studies we showed marginal predictive power for genetic risk 
profile scores, with areas under the receiver operator curves of 0.616 without age and sex 
included as covariates and 0.633 with age and sex (Figure 2, Supplementary Table 4, 
Supplementary Figure 5).3 As expected, those individuals with a genetic risk profile score 
above one standard deviation from the population mean, indicative of a roughly 34% 
increase in genetic risk scores above the control mean, had a significantly higher risk of PD 
(from meta-analysis odds ratio = 1.51, 95% CI = 1.38–1.66, p=2×10−16). In an analysis of 
outliers, we compared the 5th quintile of genetic risk scores to the 1st quintile of genetic risk 
as a reference, the odds ratio was 3.31 (95% CI = 2.55–4.30, p=2×10−16). These odds ratios 
are larger compared to earlier publications and may be due to finer scale imputation used in 
the discovery phase of this project, as well as the inclusion of additional loci and to some 
degree differing distributions of cumulative genetic risk scores across populations in the 
analysis.3,4 Cohort level summary statistics were significantly heterogeneous for both trend 
based analyses (I2 = 0.74, heterogeneity p-value = 0.003) and the comparisons of the highest 
versus lowest risk quintiles (I2 = 0.70, heterogeneity p-value = 0.01). Therefore, a random 
effects model was used to account for the heterogeneity of effect.
For each of the 28 SNPs included in the risk profile analyses, we attempted to infer 
functional consequences in frontal cortex and cerebellar tissue samples from neurologically 
normal individuals that were assayed for both genome-wide methylation and expression 
levels.26 These analyses may shed light on potential disease mechanisms for follow-up in 
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future studies. We tested cis associations (any methylation or expression probes +/− 1Mb 
from each SNP) in each of the datasets. After quality control, 25 SNPs of interest from our 
meta-analysis passed quality control in the mRNA expression datasets and all 28 SNPs of 
interest passed quality control the CpG methylation datasets. We tested multiple probes per 
SNP in each set of analyses. A total of 336 unique SNP-probe pairs were tested in the frontal 
cortex mRNA expression dataset, 865 pairs in the frontal cortex CpG methylation dataset, 
333 pairs in the cerebellar mRNA expression dataset and 1,097 pairs in the cerebellar CpG 
methylation dataset. Associations were tested using linear regression adjusting for 
appropriate covariates and resulting p-values adjusted based on the false-discovery rate 
correction (see Online Methods for details).
After correcting for multiple tests, we found 30 significant associations between SNPs of 
interest and either CpG methylation or mRNA expression (Supplementary Table 5) across 
six loci. Of particular interest were associations at rs199347 on chromosome 7 and rs823118 
on chromosome 1, as both SNPs are significantly associated with both methylation and 
expression changes in each brain region. The risk allele (A) at rs199347 on chromosome 7 
was associated with increased expression of two probes tagging NUPL2 as well as with 
decreased methylation of GPNMB in both brain regions. These data suggest that risk at the 
locus containing rs199347 might be due to increased transcription of NUPL2 further 
bolstered by decreased methylation. On chromosome 1, the risk allele (T) at rs823118 was 
associated with decreased expression of NUCKS1 and increased expression of RAB7L1, as 
well as increased DNA methylation detected by two probes close to FLJ32569 in both brain 
tissues. These data suggest a complicated risk locus at the NUCKS1/RAB7L1/FLJ32569 
region, where the same risk allele is associated with both increased expression of RAB7L1 as 
well as increased regulation of nearby genes NUCKS1 and FLJ32569. The possibility of 
multiple functionally active risk variants at this locus seems likely and is evident in the 
results of our conditional phase of analyses (Table 2). The complicated nature of this locus 
may be suggestive of some type of interaction or epistatic effect as well and it is likely that 
future functional and deep sequencing studies will be required to understand the basis of 
association at this region.
In total here we have identified 28 independent risk loci for PD; 22 found in the discovery 
phase and confirmed by replication, two previously reported loci confirmed in the 
replication phase, and four loci identified by a second risk allele exerting an effect 
independent of the primary risk allele.
URL’s
MACH2QTLv1.11 (http://www.sph.umich.edu/csg/abecasis/MaCH/download/) MiniMac 
(http://genome.sph.umich.edu/wiki/Minimac) 1000 Genomes haplotypes (http://
www.sph.umich.edu/csg/abecasis/MaCH/download/) Summary statistics of this study have 
been made available at http://www.pdgene.org (Note to the editor/reviewers: Summary 
statistics of the discovery, conditional and replication phase of this study will be made 
available to the community at the listed URL upon publication of this study)
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ONLINE METHODS
Discovery Methods
All studies willing to participate with genome-wide genotyping data on Parkinson’s diseases 
cases and controls were included in this effort. For specific details on these studies, please 
refer to individual publications [IPDGC, PD GWAS Consortium, 23&Me, CHARGE, 
PDGENE, and Ashkenazi studies].2–6,10,17,27–30 For this analysis, the 23andMe cohort was 
split into two subsets “v2” and “v3”. The “v2” designation refers to a subset of samples 
genotyped on the Illumina HumanHap550+ BeadChip, the “v3” designation refers to a 
subset of samples genotyped on the Illumina Human OmniExpress+ BeadChip. Besides 
different genotyping arrays, sample handling, ascertainment, quality control and analytic 
methods were identical across the 23andMe subsets. For 3 out of the 15 studies contributing 
to the discovery phase of analyses, population controls were utilized to some degree, totaling 
8,156 samples (Supplementary Table 1). Based on a prevalence of 2 in 1,000, we could 
estimate a misclassification of approximately 16 samples across datasets. This would likely 
have a small impact based on our large sample size, meta-analytic design and interest in 
relatively common allele frequencies.
In general standard quality control was applied by each study for sample inclusion, 
including case age at onset over 18 years, no known mutations in genes associated with 
Mendelian forms of PD (SNCA, PARK2, DJ-1, PINK1, LRRK2), minimum sample call rate 
> 95%, European ancestry confirmed through principal components or multidimensional 
scaling analyses, no relation to other samples in the meta-analysis (checked when possible 
by use of dbGAP available data) at the cousin level or closer (except in the case of 
Framingham Heart Study). Studies deriving samples from the same geographic region (or 
globally in the case of the 23AndMe dataset) cross-checked for relatedness when data access 
was permitted by using identity by descent filtering to remove related samples both within 
and across datasets contributing to the meta-analysis. If samples overlapped studies involved 
in the meta-analysis, the sample was excluded from the series with less dense genotyping. 
All participants donated DNA samples and provided informed consent for participation in 
genetics studies. Prior to imputation, SNPs were filtered using study specific criteria 
including a minimum call rate of > 95%, a minor allele frequency > 1%, Hardy-Weinberg 
equilibrium p-values > 1×10−4 in controls and non-random missingness by phenotype or 
haplotype at p-values > 1×10−4. SNPs ambiguous to strand (A/T and G/C) were also 
removed. Imputation to a standard reference panel from the 1000 Genomes Project (August 
2010 release, European ancestry only) was then carried out using miniMac on default 
settings.31
Imputed dosages were then analyzed using logistic regression for case-control studies or cox 
regression for cohort studies (Cohorts for Heart and Aging Research in Genomic 
Epidemiology (CHARGE) Consortium cohorts with incident cases) adjusting for the first 2 
eigenvectors from principal components analysis, age at onset (cases) or exam (controls), 
and sex. Eigenvectors from principal components for use as covariates were generated on a 
study specific level, with each dataset applying its own adjustment separately. This was also 
repeated in the replication by generating unique eigenvectors for each ancestry stratified 
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dataset for use as covariates. The Framingham Heart Study utilized generalized estimating 
equations clustered on pedigrees to account for family relationships.
Meta-analysis was conducted based on the fixed-effect model as implemented in METAL 
by combining summary statistics across datasets.32 At the meta-analytic level, summary 
statistics were filtered for inclusion after meeting a minimum imputation quality (RSQ from 
miniMac) of 0.30, minor allele frequency greater than 0.1% across studies, realistic beta 
coefficients where the absolute value of beta was less than 5, and passing initial quality 
control in at least three of the contributing studies. In addition, we tested novel random-
effects approaches from Han and Eskin, 2011; however, this method did not identify any 
novel loci and since the results across both methodologies were near identical, thus only 
fixed-effect results are reported here.33
Conditional Methods
Conditional analyses were undertaken using identical statistical models as in the discovery 
phase except for the inclusion of allele dosages from the most significant SNP per locus as 
an additional covariate. For each locus identified as genome-wide significant in the 
discovery phase, we reran cohort level analyses in a subset of 7 datasets with the largest 
counts of cases (due to primary data availability at the participant level, only IPDGC-NIA, 
IPDGC-NL, IPDGC-GE, 23&Me, PROGENI-GenePD, NGRC and HIHG were included) 
testing all SNPs within +/− 1MB from the 26 genome-wide significant SNPs in Table 1, 
while adjusting for the SNP with the most extreme p-value per locus. These summary 
statistics were then meta-analyzed in the same manner as the discovery phase analyses. The 
threshold for multiple test correction across secondary loci for conditional analyses was set 
to 1×10−5 based on Bonferroni correction for the number of SNPs tested across all regions. 
These methods were also applied to look for tertiary signals at all loci; three tertiary loci 
were identified, but these signals were not included in the replication array and are therefore 
not shown (data available upon request to corresponding author).
Replication Methods
Replication genotyping was carried out using the Illumina NeuroX genotyping array, with 
all samples genotyped at the National Institute on Aging’s Laboratory of Neurogenetics 
(LNG). In brief, the NeuroX array includes over 24,000 neurodegenerative-focused-variants 
added to the existing >240,000 exonic variants already available on Illumina’s Infinium 
HumanExome BeadChip. Of these neurodegenerative-focused variants, over 9,000 variants 
are dedicated to Parkinson’s disease and include tagging SNPs, proxies and technical 
replicates for loci of interest related to the discovery phase of this study. For each genome-
wide significant locus identified in the discovery phase of this study and in the conditional 
analyses, loci were covered on the array by either 5 additional proxy SNPs or 5 technical 
replicates if no proxy SNPs were available. Loci were defined as any SNP reaching a 
genome-wide significant p-value and correlated at r2 < 0.50 with any other significant SNPs 
within 250 kilobases within each genomic region of interest. Proxies were selected based on 
this 250kb threshold and LD defined using 1000 genomes European ancestry samples from 
the same panel in which the discovery series was imputed. Proxies were ranked by discovery 
phase p-value after meeting the LD threshold minimum of r2 > 0.50 with the most 
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significant SNP in the locus. Nominated proxies with the smallest discovery phase p-value 
were given precedence in replication analyses when the most significant SNP from the 
discovery phase was not available or not successfully assayed on the NeuroX array. For 
replication, 39 SNPs or their highest ranked proxy in terms of discovery phase or conditional 
p-value were utilized in the replication analyses. All summary statistics for these replication 
SNPs will be made available on the PDgene website (PDGene database (http://
www.pdgene.org). Genotypes were called using Illumina GenomeStudio, and all PD related 
SNPs analyzed for this study were manually clustered and visually inspected. Standard 
exome content variants included on the NeuroX array were called using a cluster file from 
the CHARGE Consortium based on over 60,000 samples and these variants were used for 
sample quality control.34 Over 14,000 samples genotyped on the array at LNG were used in 
the variant calling process.
From called genotypes, PD cases and neurologically normal controls were extracted and 
underwent quality control as per standard GWAS, with slight deviations from normal 
practices to account for the bias in NeuroX array content. Variants with GenTrain scores > 
0.70 (indicative of quality genotype clusters) from the standard content of the NeuroX array 
were extracted first to calculate call rates. Samples with call rates < 95% were excluded, as 
well as samples whose genetically determined sex did not match that from clinical data and 
samples exhibiting excess heterozygosity. After these initial exclusions, SNPs overlapping 
with HapMap Phase 3 samples were extracted from the previous subset and pruned for LD 
(SNPs excluded if r2 > 0.50 within a 50 SNP sliding window), as well as concurrently 
excluding SNPs with MAF < 5%, HWE p-values < 1×10−5 in controls, and per SNP 
missingness rates > 5%. At this stage, pairwise identity by descent filtering was then used to 
remove samples that were cryptically related and principal components analysis was used to 
identify samples that were to be excluded due to genetic ancestry not consistent with 
primarily European descent based on comparisons with HapMap Phase 3 reference 
populations. After these exclusions, the samples passing quality control were separated into 
distinct datasets based on the country and center of origin. All samples in the replication 
series were ascertained as follows: case ascertainment was based on UK brain bank criteria 
from clinic visit, or use of PD medication or medical records of PD diagnosis by clinician; 
recruited controls include individuals free of known neurological disease either by clinical 
assessment and/or self-report. The final replication set consisted of 5,353 cases and 5,551 
controls with all relevant phenotypic data for this analysis stratified across American (2,407 
cases and 2,782 controls), French (553 cases, 474 controls), German (1,044 cases and 871 
controls), Greek (944 cases and 877 controls) and British (405 cases and 547 controls) 
participants.
Within each subset of samples passing quality control, principal components analysis was 
used to generate eigenvectors for use as covariates to account for population substructure 
within each cohort based on common high quality SNPs that have also been LD pruned as 
described above. Within each subset of samples, logistic regression adjusting for the first 2 
eigenvectors from principal components analysis, age at onset (cases) or exam (controls), 
and sex was used to examine associations of each nominated SNP with PD. After subset 
summary statistics were generated, fixed-effect meta-analyses were used to generate 
aggregate summary statistics and quantify heterogeneity across subsets for all 39 replication 
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target SNPs placed on the array. As a note, regions around these SNPs +/− 500kb were not 
included in the sample QC procedure, and these 39 SNPs were manually clustered to 
evaluate quality genotyping.
Risk Profiling Methods
Risk profiles were generated incorporating three groups of SNPs. The first group included 
genome-wide significant index SNPs (or their proxies) from the discovery phase that 
replicated in the independent replication phase (n=22). The second group comprised 
conditional SNPs that validated in the replication phase (n=4). The third group consisted of 
previously reported SNPs that did not quite meet genome-wide significance in the discovery 
phase but provided evidence of association in the replication phase (n=2). These risk profiles 
were generated using weights based on effect estimates from the discovery phase of this 
study using methodologies described in detail elsewhere.3,4,11,35 In brief, genetic risk scores 
were scaled on a per SNP basis using effect estimates from the discovery phase then applied 
to the genotype data generated for the samples in the replication phase to create the dataset 
for analyses of the risk profiles. Within each subset of the replication sample series, overall 
trend tests for PD risk were evaluated using logistic regression with the risk profile score 
predicting affection status adjusted for the first 2 eigenvectors from PCA as well as age and 
sex. Each subset was also divided into quintiles based on their risk profile scores, and 
similar logistic regression models were used to estimate risk associated in each of the 4 
higher risk quintiles compared to the lowest risk quintile. All risk profile summary statistics 
were meta-analyzed across subsets using random-effects to account for effect heterogeneity. 
To evaluate clinical predictability of PD, all risk profiles were combined into one model 
across replication subsets, adjusting for age, sex and cohort/subset membership in receiver-
operator curve analyses.
Expression and Methylation Quantitative Trait Locus Methods
Overlapping SNPs identified in the discovery phase (Tables 1 and 2) that were successfully 
genotyped or imputed in the combined North American Brain Expression Consortium 
(NABEC) and United Kingdom Brain Expression Consortium (UKBEC) datasets were 
tested for association with proximal expression and methylation levels (GSE36192). Allelic 
dosages of SNPs of interest were tested for association with all methylation and expression 
probes within +/− 1MB from each SNP using linear regression adjusting for covariates of 
gender, age at death, the first two component vectors from multi-dimensional scaling, post 
mortem interval (PMI), brain bank and batch in which preparation or hybridization were 
performed, using MACH2QTLv1.11 (http://www.sph.umich.edu/csg/abecasis/MaCH/
download/). These analyses were run separately for frontal cortex and cerebellar regions, 
each with analyses focusing on methylation (292 samples) or expression (399 samples). For 
these four analyses, significance was based on standard FDR adjustments for multiple 
testing. Further details on consortia membership, acknowledgments and full methods for the 
expression and methylation portions of this study, please see Supplementary Note.
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EXPRESSION AND METHYLATION METHODS
Frozen frontal cortex and cerebellar samples were obtained from > 399 self-reported 
European ancestry samples without determinable neuropathological evidence of 
disease.26,36 Genomic DNA was extracted with phenol-chloroform. Bisulfite converted 
DNA and assayed at > 27,000 sites on the Illumina Infinium HumanMethylation27 
BeadChips. MRNA expression levels were assayed using Illumina HumanHT-12 v3 
Expression Beadchips. In brief, Individual probes were excluded from analyses if the p-
value for detection was > 0.01 or there was less than 95% completeness of data per probe, 
and samples were excluded if <95% of probes were detected. Probes were also removed if 
an analyzed SNP was within the probe or the probe mapped ambiguously to multiple 
locations in the genome. Expression data were cubic spline normalized and log2-
transformed prior to analyses.
Each tissue sample was genotyped using the Illumina HumanHap550 v3, Human610-Quad 
v1 or Human660W-Quad v1 Infinium Beadchips, shared SNPs were extracted prior to QC 
and imputation. Standard GWAS quality control was undertaken with inclusion criteria such 
as: minimum call rate 95% for both participants and SNPs, MAF > 0.01, HWE > 1×10−7, no 
first-degree relatives in the sample collection (identity by descent score < 0.125 in PLINK), 
and European ancestry confirmed by multidimensional scaling analyses.
Data were imputed using MiniMac (http://genome.sph.umich.edu/wiki/Minimac) to the most 
recent data freeze of 1000 Genomes haplotypes (http://www.sph.umich.edu/csg/abecasis/
MaCH/download/1000G.2012-03-14.html) using default settings. All imputed SNPs were 
filtered for a minimum imputation quality of 0.30. After quality control, data were available 
for > 10 million SNPs, with expression data on 399 samples (9814 probes from the frontal 
cortex and 9587 probes in cerebellum) and methylation data on 292 samples (27465 CpG 
sites in the frontal cortex tissue samples and 27419 CpG sites in the cerebellum).
Linear regression models were utilized to estimate associations between allele dosages of 
per SNP and gene expression or methylation levels adjusted for covariates of gender, age at 
death, the first two component vectors from multi-dimensional scaling, post mortem interval 
(PMI), brain bank and batch in which preparation or hybridization were performed, using 
MACH2QTLv1.11 (http://www.sph.umich.edu/csg/abecasis/MaCH/download/). Analyses 
were carried out separately for each brain region and each array type. Only probes within +/
− 1MB were analyzed to test only cis associations. From these analysis results, data were 
mined for 28 replciated SNPs of interest included in Table 1 and Table 2.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Manhattan plot of discovery phase meta-analyses.
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Figure 2. 
Forest plots describing cohort level and summary effects of risk profile analyses.
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